UCLA researchers have discovered the molecular basis of, and identified potential treatment for, an incurable disease known as inclusion body myopathy, Paget disease with frontotemporal dementia, or IBMPFD. Using both genetically engineered fruit flies that have the fly equivalent of the disease gene as well as cells from people with IBMPFD, the researchers discovered how mutations carried by those with IBMPFD cause cellular damage. They also identified two compounds that are able to reverse the effects of IBMPFD-associated mutations in flies and human IBMPFD cells. The findings suggest potential strategies to combat IBMPFD and other degenerative diseases, including amyotrophic lateral sclerosis, commonly known as ALS.
IBMPFD is an inherited disorder that affects the muscles, the brain and bones. Most people with the disorder show progressive muscle weakness, or myopathy, leading to mobility loss or even respiratory failure. Others develop dementia that predominantly affects language and behavior. No treatment is available to halt progression of the disease. Prior studies showed that mutations in a gene that encodes Valosin-Containing Protein, known as VSP, cause IBMPFD and some forms of ALS. Moreover, in people with IBMPFD, mitochondria, the energy-generating powerhouse of the cell, do not produce energy properly. However, it was not clear how VSP mutations disrupt mitochondria and how this disruption leads to disease.
The team created fruit flies that are given the disease in their muscles, which results in multiple defects, including muscle cell death, similar to that seen in patients. In addition, abnormally small, fragmented mitochondria appeared, a sign of mitochondrial distress. This led the team to examine a protein called Mitofusin which controls mitochondria fusion, maintaining mitochondrial energy-production capacity in healthy cells. The team showed that VSP normally degrades Mitofusin, but mutant VCP is abnormally overactive, and promotes excessive degradation of Mitofusin. This discovery explains how cellular damage occurs. Most importantly, flies fed VCP-inhibiting compounds showed reversal of muscle wasting and mitochondrial fragmentation. Patient cells treated with the same compounds showed similar positive responses.
Biomedical researchers are increasingly aware that defects in mitochondrial fusion are a hallmark of conditions ranging from Parkinson’s disease, heart disease to diabetes. This paper reveals how mutant VCP can cause cellular destruction seen in IBMPFD by interfering with proteins responsible for controlling mitochondrial fusion. Importantly, VCP inhibitors can reverse the pathology of IBMPFD in flies and in patient cells. VCP inhibitors are currently being studied in clinical trials for cancer. This raises the possibility of using VCP inhibitors for treatments of IBMPFD and other diseases caused by VCP mutations, such as ALS, peripheral neuropathy and hereditary spastic paraplegia.
The senior author of the study is Dr. Ming Guo, and the first author is Dr. Ting Zhang, both of the department of neurology in the David Geffen School of Medicine at UCLA. Additional co-authors include Dr. Prashant Mishra, Bruce Hay and Dr. David Chan, all working at California Institute of Technology.
The research is published in the journal eLife.
This work was supported by the National Institutes of Health (NIA R01, NINDS Eureka award), the Natalie R. and Eugene S. Jones Fund in Aging and Neurodegenerative Disease Research, the Kenneth Glenn Family Foundation, the McKnight Neuroscience Foundation and the Ellison Medical Foundation.